Søgeord (hiv) valgt.
13 emner vises.
1
Updated U.S. Public Health Service Guideline for Testing of Transplant Candidates Aged
Morbidity and Mortality Weekly Report (MMWR), 30.06.2022
Tilføjet 30.06.2022
This report describes updated public health service guidelines for testing transplant candidates under 12 years of age for HIV, Hepatitis B, and Hepatitis C.
Læs mere
2
HIV Testing Before and During the COVID-19 Pandemic - United States, 2019-2020
Morbidity and Mortality Weekly Report (MMWR), 23.06.2022
Tilføjet 23.06.2022
This report describes new HIV diagnoses reported to CDC from 2019 to 2020 and declines in HIV testing during the same period.
Læs mere
3
Primary Care Doc Education May Increase PrEP Prescribing
Medscape Infectious Diseases, 15.06.2022
Tilføjet 15.06.2022
Educating primary care clinicians about preexposure prophylaxis for HIV could help ease the shortage in clinicians who prescribe the drugs, a study found.
Læs mere
4
Screening for Cervical Dysplasia and Cancer in HIV
Medscape Infectious Diseases, 8.06.2022
Tilføjet 8.06.2022
Cervical cancer is an AIDS-defining illness and is a leading cause of cancer death among women with HIV.
Læs mere
5
Monkeypox infection presenting as genital rash, Australia, May 2022
Yael Hammerschlag, Gina MacLeod, Georgina Papadakis, Asiel Adan Sanchez, Julian Druce, George Taiaroa, Ivana Savic, Jamie Mumford, Jason Roberts, Leon Caly, Deborah Friedman, Deborah A Williamson, Allen C Cheng and James H McMahon
Eurosurveillance latest updates, 2.06.2022
Tilføjet 3.06.2022
Rapid diagnosis and whole genome sequencing confirmed a case of monkeypox in an HIV-positive individual receiving antiretroviral therapy. The patient had a normal CD4+ T-cell count and suppressed HIV viral load and presented with a genital rash in Melbourne, Australia after return from Europe in May 2022. He subsequently developed systemic illness and disseminated rash and 11 days after symptom onset, he was hospitalised to manage painful bacterial cellulitis of the genital area.
Læs mere
6
Factors Associated with Use of HIV Prevention and Health Care Among Transgender Women - Seven Urban Areas, 2019-2020
Morbidity and Mortality Weekly Report (MMWR), 19.05.2022
Tilføjet 30.05.2022
This report describes economic circumstances associated with transgender women accessing HIV prevention and healthcare.
Læs mere
7
With COVID, 2020 Was 'Lost Year' in Fight Against HIV
Medscape Infectious Diseases, 25.05.2022
Tilføjet 26.05.2022
Due to the COVID-19 pandemic, 2020 was likely a "lost year" in the public health battle against the long-lasting HIV epidemic in the US, a public health official says.
Læs mere
8
Counterfeit HIV Drugs: Justice Department Opens Investigation
Medscape Infectious Diseases, 11.04.2022
Tilføjet 12.04.2022
A sophisticated criminal enterprise has been operating at scale to distribute and profit from counterfeit HIV drugs. The details read like a best-selling crime novel.
Læs mere
9
Judge Rules US Military Can't Discharge Troops With HIV
Medscape Infectious Diseases, 11.04.2022
Tilføjet 11.04.2022
Advocates say it's one of the strongest rulings in years for people living with HIV.
Læs mere
10
HIV, STI and renal function testing frequency and STI history among current users of self-funded HIV pre-exposure prophylaxis, a cross-sectional study, Germany, 2018 and 2019
Uwe Koppe, Janna Seifried, Ulrich Marcus, Stefan Albrecht, Klaus Jansen, Heiko Jessen, Barbara Gunsenheimer-Bartmeyer and Viviane Bremer
Eurosurveillance latest updates, 7.04.2022
Tilføjet 8.04.2022
Introduction
Users of pre-exposure prophylaxis (PrEP) require periodic testing for HIV, sexually transmitted infections (STI) and renal function. Before PrEP was made free of charge through statutory health insurance in late 2019, PrEP users in Germany had to pay for testing themselves.
Aim
We investigated self-reported HIV, STI and renal function testing frequencies among self-funded PrEP users in Germany, factors associated with infrequent testing, and STI diagnoses.
Methods
A cross-sectional anonymous online survey in 2018 and 2019 recruited current PrEP users via dating apps for men who have sex with men (MSM), a PrEP community website, anonymous testing sites and friends. We used descriptive methods and logistic regression for analysis.
Results
We recruited 4,848 current PrEP users. Median age was 37 years (interquartile range (IQR): 30–45), 88.7% identified as male, and respectively 26.3%, 20.9% and 29.2% were tested less frequently for HIV, STI and renal function than recommended. Participants with lower STI testing frequency were significantly less likely to report STI diagnoses during PrEP use, especially among those with many partners and inconsistent condom use. Factors most strongly associated with infrequent testing included not getting tested before starting PrEP, using PrEP from informal sources and on-demand/intermittent PrEP use.
Discussion
In a setting of self-funded PrEP, many users obtained medical tests less frequently than recommended, which can lead to missed diagnoses. Barriers to testing should be addressed to enable proper medical supervision. The suitability of testing frequencies to PrEP users with less frequent risk exposures needs to be evaluated.
Læs mere
11
HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019
Hendrik Streeck, Klaus Jansen, Trevor A Crowell, Allahna Esber, Heiko K Jessen, Christiane Cordes, Stefan Scholten, Stephan Schneeweiss, Norbert Brockmeyer, Christoph D Spinner, Markus Bickel, Stefan Esser, Jukka Hartikainen, Albrecht Stoehr, Clara Lehmann, Ulrich Marcus, Jörg Janne Vehreschild, Alexandra Knorr, Anna-Lena Brillen, Carsten Tiemann, Merlin L Robb and Nelson L Michael
Eurosurveillance latest updates, 7.04.2022
Tilføjet 8.04.2022
Introduction
Despite increased use of pre-exposure prophylaxis (PrEP) in Germany, HIV infection rates are not declining and little is known about how this prevention method affects the prevalence of sexually transmitted infections (STI) among men who have sex with men (MSM).
Aim
We studied, in a large multicentre cohort, STI point prevalence, co-infection rates, anatomical location and influence of PrEP.
Methods
The BRAHMS study was a prospective cohort study conducted at 10 sites in seven major German cities that enrolled MSM reporting increased sexual risk behaviour. At screening visits, MSM were tested for Mycoplasma genitalium (MG), Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Treponema pallidum (TP), and given a behavioural questionnaire. With binomial regression, we estimated prevalence ratios (PR) and 95% confidence intervals (CI) for the association of PrEP and STI.
Results
We screened 1,043 MSM in 2018 and 2019, with 53.0% currently using PrEP. At screening, 370 participants (35.5%) had an STI. The most common pathogen was MG in 198 (19.0%) participants, followed by CT (n = 133; 12.8%), NG (n = 105; 10.1%) and TP (n = 37; 3.5%). Among the 370 participants with at least one STI, 14.6% (n = 54) reported STI-related symptoms. Infection prevalence was highest at anorectal site (13.4% MG, 6.5% NG, 10.2% CT). PrEP use was not statistically significant in adjusted models for STI (PR: 1.10; 95% CI: 0.91–1.32), NG/CT, only NG or only CT.
Conclusions
Prevalence of asymptomatic STI was high, and PrEP use did not influence STI prevalence in MSM eligible for PrEP according to national guidelines.
Læs mere
12
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission
Jeffrey CD Koole, Feline de la Court, Matthijs RA Welkers, Kenneth Yap, Janneke E Stalenhoef, Suzanne Jurriaans, Henry JC de Vries, Eline LM Op de Coul, Maria Prins and Elske Hoornenborg
Eurosurveillance latest updates, 7.04.2022
Tilføjet 8.04.2022
In August 2021, a man who has sex with men was diagnosed with HIV-1 infection despite using event-driven pre-exposure prophylaxis for over 2 years with self-reported excellent adherence. Sequencing identified resistance-associated mutations (RAM) M184V and K65R, conferring resistance to emtricitabine and tenofovir, and RAM V108I and E138A. Background RAM prevalence was two of 164 (1.2%) new HIV diagnoses in Amsterdam (2017–19). We reiterate the need for frequent HIV testing among PrEP users and additional testing in case of symptoms.
Læs mere
13
Lessons Learned from Programmatic Gains in HIV Service Delivery During the COVID-19 Pandemic - 41 PEPFAR-Supported Countries, 2020
Morbidity and Mortality Weekly Report (MMWR), 24.03.2022
Tilføjet 24.03.2022
This report describes programmatic gains of HIV treatment during the pandemic.
Læs mere